| 000 | 01840 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517002620.0 | ||
| 264 | 0 | _c20151104 | |
| 008 | 201511s 0 0 eng d | ||
| 022 | _a1471-2334 | ||
| 024 | 7 |
_a10.1186/s12879-014-0587-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWei, Sung-Hsi | |
| 245 | 0 | 0 |
_aThe safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study. _h[electronic resource] |
| 260 |
_bBMC infectious diseases _cNov 2014 |
||
| 300 |
_a587 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Viral _xblood |
| 650 | 0 | 4 | _aAntibody Formation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHemagglutination Inhibition Tests |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunization, Secondary |
| 650 | 0 | 4 |
_aInfluenza A Virus, H5N1 Subtype _ximmunology |
| 650 | 0 | 4 |
_aInfluenza Vaccines _ximmunology |
| 650 | 0 | 4 |
_aInfluenza, Human _xprevention & control |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPandemics |
| 650 | 0 | 4 |
_aPolysorbates _xtherapeutic use |
| 650 | 0 | 4 |
_aSqualene _ximmunology |
| 650 | 0 | 4 | _aVaccination |
| 650 | 0 | 4 | _aVietnam |
| 650 | 0 | 4 | _aWorld Health Organization |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aLiu, Ming-Tsan | |
| 700 | 1 | _aTsai, Yao-Chou | |
| 700 | 1 | _aLiao, Chung-Hsin | |
| 700 | 1 | _aChen, Chih-Ming | |
| 700 | 1 | _aWang, Wei-Yao | |
| 700 | 1 | _aHuang, Yi-Lung | |
| 700 | 1 | _aChang, Feng-Yee | |
| 700 | 1 | _aChou, Pesus | |
| 773 | 0 |
_tBMC infectious diseases _gvol. 14 _gp. 587 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12879-014-0587-z _zAvailable from publisher's website |
| 999 |
_c24352568 _d24352568 |
||